Perlara

Perlara identified a critical bottleneck in rare disease drug development: families with sick children faced a decade-long wait for treatments that pharmaceutical companies deemed unprofitable to pursue. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Parents of children with ultra-rare genetic disorders experienced this most acutely—their children's conditions affected fewer than 10,000 people globally, making traditional drug development economically unviable. The problem was measurable through clear metrics: zero approved treatments existed for thousands of rare diseases, and families documented their children's disease progression through medical records and genetic sequencing. Existing alternatives were limited to off-label drug repurposing attempts by desperate families or waiting for government grants to fund academic research. Early validation came when Perlara launched PerlQuests and discovered that highly motivated rare disease families would actively participate in R&D efforts, providing genetic data and patient avatars for screening. The fact that families volunteered their time and resources—rather than requiring recruitment incentives—signaled genuine demand for an alternative pathway to treatment discovery.